The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
Authors
Keywords
Cost-effectiveness analysis, Markov models, Rheumatoid arthritis, Comparators, Systematic reviews, Indirect costs, Drug therapy, Health economics
Journal
PLoS One
Volume 10, Issue 3, Pages e0119683
Publisher
Public Library of Science (PLoS)
Online
2015-03-18
DOI
10.1371/journal.pone.0119683
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2014) Jackie L Nam et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
- (2014) K Malottki et al. HEALTH TECHNOLOGY ASSESSMENT
- Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents
- (2013) Axel Finckh et al. ANNALS OF INTERNAL MEDICINE
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis
- (2012) Nicole W. Tsao et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis
- (2012) Christine M. Nguyen et al. PHARMACOECONOMICS
- Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
- (2012) Kalle J. Aaltonen et al. PLoS One
- Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China
- (2012) Bin Wu et al. PLoS One
- Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy
- (2012) Alexander Diamantopoulos et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment
- (2011) Gisela Kobelt et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective
- (2011) Lydia G. Schipper et al. RHEUMATOLOGY
- Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
- (2011) David C. Hoaglin et al. VALUE IN HEALTH
- Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis
- (2011) E. J. Soini et al. JOURNAL OF MEDICAL ECONOMICS
- Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
- (2010) M. Schoels et al. ANNALS OF THE RHEUMATIC DISEASES
- Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
- (2010) J. L. Nam et al. ANNALS OF THE RHEUMATIC DISEASES
- Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden
- (2010) Ingrid Lekander et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
- (2010) T. A. Hallinen et al. RHEUMATOLOGY
- Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review
- (2010) Gabrielle van der Velde et al. ARTHRITIS CARE & RESEARCH
- Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis
- (2009) Wilbert B. Van den Hout et al. ARTHRITIS AND RHEUMATISM
- Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden
- (2009) Peter Lindgren et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States
- (2009) Yong Yuan et al. JOURNAL OF MEDICAL ECONOMICS
- Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis
- (2008) Allan J. Wailoo et al. ARTHRITIS AND RHEUMATISM
- UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug
- (2008) Adrian Kielhorn et al. CURRENT MEDICAL RESEARCH AND OPINION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now